Lazine-M is a combination drug relevant in contexts involving heightened systemic burden, generally assisting with maintaining functional stability during phases when symptoms become more noticeable. It contains Levocetirizine and Montelukast, which play a role in managing symptoms related to inflammatory or irritative states.

The combination is relevant in therapeutic domains where additional symptomatic support is needed. The Montelukast component is indicated for the prophylaxis and chronic treatment of asthma, the acute prevention of exercise-induced bronchoconstriction, and the relief of symptoms of allergic rhinitis (seasonal and perennial). This medication may assist with managing manifestations of conditions involving episodic or fluctuating manifestations, such as chronic hives (urticaria), a condition where symptoms may intensify temporarily.

It is applied in addressing symptom clusters that may become intense or disruptive, such as those that interfere with daily functioning, including sneezing, runny nose, itchy/watery eyes, and nasal congestion. This supportive relief may help patients cope more steadily with symptom fluctuations. The supportive relief contributes to easing the overall symptom load.

---

Quick Fact: Relevant for easing symptoms related to inflammatory or irritative states.

Who can and cannot use Lazine-M?

Eligibility for Lazine-M (Levocetirizine/Montelukast) is strictly defined by regulatory documents based on age, organ function, and hypersensitivity. The medicine is primarily indicated for use in adults and adolescents 15 years of age and older.

---

Populations for Whom Use is Prohibited or Restricted

Classification	Population or Condition
Contraindicated	Individuals with known hypersensitivity to the active ingredients or Cetirizine.
Contraindicated	Patients with severe renal impairment (creatinine clearance < 10 mL/min) or anuria.
Contraindicated	Children aged 6 to 11 years with renal impairment.
Not Recommended	Pregnant or breastfeeding women, due to insufficient data or excretion into breast milk.
Not Established	Pediatric patients under 15 years of age for the tablet strength.

---

Use Requires Caution

Use is restricted, and caution is specifically advised for patients with impaired hepatic (liver) function, those with moderate renal impairment, and individuals with a history of epilepsy or factors predisposing to urinary retention.

Interactions with other medicines and products

This section describes officially documented interaction patterns for the active ingredients Levocetirizine and Montelukast, based strictly on regulatory prescribing information.

Pharmacokinetic Interactions

Montelukast is a substrate for hepatic enzymes CYP3A4, CYP2C8, and CYP2C9, meaning co-administered substances can alter its plasma concentration. The regulatory labeling states that co-administration with the potent CYP2C8 inhibitor Gemfibrozil significantly increases Montelukast exposure. Conversely, co-administration with the potent CYP inducer Rifampin is documented to reduce the Montelukast plasma concentration by approximately 40%. The Levocetirizine component is primarily excreted unchanged, indicating a lower risk of CYP-mediated interaction with other medicines. Montelukast does not significantly alter the exposure of co-administered drugs like Theophylline or Prednisone.

Pharmacodynamic and Substance Interactions

Co-administration of the Levocetirizine component with alcohol or other Central Nervous System (CNS) depressants (e.g., sedatives) may result in additive CNS effects and increased impairment. No clinically significant food interaction is documented for either component. Since Levocetirizine is eliminated primarily by renal excretion, its interaction profile requires caution in patients with renal impairment, where reduced clearance can lead to higher systemic exposure.

Lazine-M acts through simultaneous blockade of two independent signaling pathways involving amine and lipid inflammatory mediators. This approach engages distinct, complementary mechanisms that result in the modulation of two core inflammatory pathways.

Peripheral H1 Receptor Antagonism

This domain focuses on the action of Levocetirizine, which functions as a highly selective antagonist at peripheral Histamine H1 Receptors ( H1R). By blocking histamine's access to the receptor, this mechanism suppresses histamine's signaling, limiting excessive vascular permeability and dampening nerve stimulation. This results in the regulation of fluid exudation and sensory nerve signaling.

CysLT1 Receptor Antagonism and Smooth Muscle Regulation

This domain focuses on the action of Montelukast, a selective antagonist of the Cysteinyl Leukotriene Receptor Type 1 ( CysLT1R). By preventing the signaling of leukotrienes, this mechanism inhibits the primary drivers of smooth muscle contraction and tissue fluid accumulation in the respiratory tract. This results in the maintenance of smooth muscle relaxation and a decrease in inflammatory tissue fluid accumulation.

Mechanistic Complementation

The combination exhibits mechanistic complementation by simultaneously blocking signaling pathways mediated by both amine ( H1R) and eicosanoid ( CysLT1R) mediators. This dual-level modulation simultaneously affects mechanisms governing immediate vascular effects and chronic inflammatory cell recruitment (e.g., eosinophil migration). This combined action results in a **wide-ranging modulation of the underlying biological processes.***>>

How to Use Lazine-M

The Lazine-M fixed-dose combination (FDC) is administered via the oral route as a film-coated tablet, combining Levocetirizine 5 mg and Montelukast 10 mg. The standard administration protocol for adults is one tablet taken once daily. This once-daily schedule is designated for consumption in the evening and may be taken consistently with or without food. The tablet must be swallowed whole with an adequate amount of liquid.

---

Administration Patterns and Adjustments

Official guidelines stipulate that the medication may be used on an intermittent or "as-needed" basis for specific conditions. This structured approach permits the cessation of dosing when symptoms resolve and resumption when they reappear.

For patients with impaired renal function, a mandatory dose adjustment is required, as outlined in the official prescribing information for the levocetirizine component. This adjustment is based on the patient's creatinine clearance (CLcr). The use of the Lazine-M FDC is prohibited in patients with severe renal impairment (CLcr less than 10 mL/min). Conversely, no specific dose adjustment is needed for patients with isolated mild to moderate hepatic impairment. The 5 mg/10 mg strength is generally reserved for adults and adolescents 15 to 18 years of age and older, with lower, separate strengths available for younger pediatric populations.

Evidence for Use in Allergic Rhinitis (AR)

Research has primarily examined Lazine-M in conditions characterized by fluctuating or episodic manifestations, such as seasonal and perennial Allergic Rhinitis (AR). The evidence available was explored through short-term, randomized controlled trials (RCTs) and systematic reviews. Studies often included monotherapy or placebo as a comparator.

The studies monitored outcomes related to physical discomfort, such as the Total Nasal Symptom Score (TNSS), and outcomes reflecting daily functioning, captured through quality of life questionnaires. Findings describe patterns observed in the studies, with measurements taken on symptoms during the short study period, typically up to four weeks.

---

Evidence for Use in Allergic Rhinitis with Coexisting Asthma

Lazine-M was evaluated in research contexts involving patients who experience both allergic rhinitis and coexisting mild-to-moderate asthma. Studies monitored the effects of this combination therapy across two distinct but linked conditions. The research examined both patient-reported outcomes (such as perceived discomfort) and objective data from pulmonary function testing, such as the Forced Expiratory Volume in 1 second (FEV1).

Studies monitored the patterns of symptoms in the observed populations. This evidence contributes to the body of evidence for these coexisting conditions, but the core trials involved short-term follow-up periods.

---

Evidence Gaps and Areas of Uncertainty

The evidence base across all studied conditions reflects that follow-up durations were limited, often spanning only about four weeks. Therefore, long-term effects are not fully established, and certainty regarding the sustained use of Lazine-M remains low. Limited information exists for long-term outcomes, such as the durability of reported changes beyond the short-term study period.

Research highlights that data for certain groups, such as very young children, older adults, or those with specific comorbid conditions like Chronic Urticaria (CU), remain insufficient. Comparative evidence is also lacking against several other therapeutic strategies. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. Efficacy of levocetirizine/montelukast fixed-dose combination in patients with chronic urticaria unresponsive to standard antihistamine dose

Common questions about Lazine-M (FAQ)

---

Q: How quickly does Lazine-M start to work?

Official information regarding the levocetirizine component suggests a rapid time to peak concentration. The time it takes for the drug to reach its highest measurable level in the bloodstream (Tmax) is approximately 0.9 hours after a single oral dose. This time measurement indicates how quickly the active component reaches its peak measurable level in the body.

---

Q: Can Lazine-M be taken long-term?

Montelukast, one of the components in Lazine-M, is approved for the long-term treatment of certain chronic conditions, such as asthma. However, official safety communications indicate that the benefits and risks should be carefully evaluated, particularly when the medicine is used long-term for conditions like allergic rhinitis. This evaluation is due to the potential for serious neuropsychiatric events associated with the montelukast component.

---

Q: What happens if I miss taking a dose of Lazine-M?

Regulatory instructions for the components of Lazine-M state the patient should skip the missed dose entirely. The patient should then take the next dose at the regularly scheduled time. Official documents specify that two doses must not be taken together to compensate for a forgotten one.

---

Q: Is Lazine-M the same as [similar common drug name]?

Lazine-M is formally defined in regulatory documents as a Fixed-Dose Combination (FDC) product. This means it combines two distinct active medicines—levocetirizine and montelukast—in a single tablet. This combination structure is what distinguishes it from single-entity products that contain only one active ingredient.

---

Q: Are there any common foods to avoid while on Lazine-M?

Official prescribing information indicates that this medicine may be taken with or without food. There are no documented specific food restrictions that must be followed while taking Lazine-M.

---

Q: Are there different strengths or versions of Lazine-M available?

The components of Lazine-M are available in multiple dosage forms as listed in official documents. These include the standard film-coated tablet (5 mg levocetirizine/10 mg montelukast), as well as chewable tablets, oral granules, and an oral solution for different patient populations.

---

Q: What kind of research has been published about Lazine-M?

Regulatory documents detail that the drug’s efficacy was established based on evidence from randomized, double-blind, placebo-controlled clinical trials. These types of studies are the foundation for the regulatory approval of the medicine for conditions such as allergic rhinitis and asthma.

---

Q: Is there a generic version of Lazine-M available?

The two primary active ingredients in Lazine-M, levocetirizine and montelukast, are individually available in generic versions. This happened after the period of market exclusivity ended for the single-entity components.

---

Q: What happens if I stop taking Lazine-M suddenly?

Official safety guidance indicates that the montelukast component is discontinued immediately if serious neuropsychiatric events occur. Furthermore, regulatory labels note that the levocetirizine component has been associated with reports of intense pruritus (itching) when the medicine is discontinued.

---

Q: Do official guidelines mention taking Lazine-M with food or on an empty stomach?

Official guidelines state that the tablet may be taken consistently with or without food. This flexibility of administration is detailed in the instructions for use found in the official documents.

---

Q: Does Lazine-M interact with contraceptive pills?

Clinical studies examining the montelukast component reported no clinically important effects on the pharmacokinetics (how the body handles the drug) of common oral contraceptives. Specifically, no significant interaction was found with ethinyl estradiol or norethindrone.

---

Q: Is it possible to take Lazine-M only when symptoms appear?

Official prescribing guidelines permit the use of this medicine on an intermittent or 'as-needed' basis for the treatment of certain conditions, such as seasonal allergic rhinitis. This allowance is detailed in the administration patterns section of the regulatory documents.

---

Q: Are there any known interactions between Lazine-M and grapefruit juice?

Official regulatory prescribing information for the active components of Lazine-M does not note any specific warnings or documented interactions between the medicine and grapefruit or grapefruit juice.

---

Q: Does Lazine-M contain any ingredients that cause allergic reactions?

Lazine-M is contraindicated (prohibited) for individuals with a known hypersensitivity to the active ingredients (levocetirizine or montelukast) or to cetirizine. The full list of inactive ingredients (excipients) is detailed in the official drug label and are available for review regarding potential personal allergies.

---

Q: What type of regulatory body approved Lazine-M for sale?

Lazine-M and its components are approved for sale by governmental regulatory authorities around the world. Examples of these bodies include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

---

Q: Is Lazine-M safe to use if I have kidney issues?

Official labeling describes a mandatory dose adjustment for patients with mild to moderate impaired renal (kidney) function. Furthermore, use of the medicine is contraindicated (prohibited) in patients with severe renal impairment (creatinine clearance less than 10 mL/ min).

How to Store and Dispose of Lazine-M Tablet

Lazine-M Tablet (Levocetirizine and Montelukast) must be stored and disposed of according to official regulatory specifications to maintain its stability and ensure safety.

---

Official Storage Requirements

The medicine is required to be kept at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and must not be frozen or refrigerated. The tablets must be stored in the original container or blister packaging, with the container kept tightly closed to protect the contents from light and moisture. It is mandatory to keep this medicine out of the sight and reach of children and pets at all times.

---

Disposal Instructions

Do not dispose of unused or expired Lazine-M via household trash or by flushing it down a toilet. The product must be disposed of according to local regulations for pharmaceutical waste, such as returning it to a pharmacy or using a designated medicine take-back program.